Logo image
Inhibition of Apoptosis in Pediatric Cancer by Survivin
Journal article   Peer reviewed

Inhibition of Apoptosis in Pediatric Cancer by Survivin

Ayman Samkari and Rachel A. Altura
Current pediatric reviews, v 7(4)
Nov 2011

Abstract

Life Sciences & Biomedicine Pediatrics Science & Technology
An estimated 17.6 per 100,000 new cases of childhood cancer are diagnosed each year in the United States. The major subtypes of childhood cancer include leukemia, central nervous system tumors, lymphoma, neuroblastoma, rhabdomyosarcoma, osteosarcoma, Ewing sarcoma, Wilms tumor, Germ cell tumors, and other rare tumors. Despite improvements in the diagnosis and treatment of these tumors over the last 30 years, subsets of children still have poor outcomes and many others have significant morbidity. Dysregulation of apoptotic pathways has been shown to contribute to tumor formation as well as resistance to therapy in both pediatric and adult malignancies. Survivin, the smallest member of the inhibitor of apoptosis protein (IAP) family, is highly expressed in diverse cancers and correlates with decreased patient survival. Here, we review the current literature on Survivin expression in pediatric cancer, its relationship to clinical outcome and potential therapeutic options to target this protein in pediatric cancer.

Metrics

11 Record Views
1 citations in Scopus

Details

UN Sustainable Development Goals (SDGs)

This publication has contributed to the advancement of the following goals:

#3 Good Health and Well-Being

InCites Highlights

Data related to this publication, from InCites Benchmarking & Analytics tool:

Web of Science research areas
Pediatrics
Logo image